Document Detail

The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study.
MedLine Citation:
PMID:  19074594     Owner:  NLM     Status:  MEDLINE    
Hypertrophic cardiomyopathy is caused by mutations in the genes that encode sarcomeric proteins and is primarily characterized by unexplained left ventricular hypertrophy, impaired cardiac function, reduced exercise tolerance, and a relatively high incidence of sudden cardiac death, especially in the young. The extent of left ventricular hypertrophy is one of the major determinants of disease prognosis. Angiotensin II has trophic effects on the heart and plays an important role in the development of myocardial hypertrophy. Here in a double-blind, placebo-controlled, randomized study, we show that the long-term administration of the angiotensin II type 1 receptor antagonist candesartan in patients with hypertrophic cardiomyopathy was associated with the significant regression of left ventricular hypertrophy, improvement of left ventricular function, and exercise tolerance. The magnitude of the treatment effect was dependent on specific sarcomeric protein gene mutations that had the greatest responses on the carriers of ss-myosin heavy chain and cardiac myosin binding protein C gene mutations. These data indicate that modulating the role of angiotensin II in the development of hypertrophy is specific with respect to both the affected sarcomeric protein gene and the affected codon within that gene. Thus, angiotensin II type 1 receptor blockade has the potential to attenuate myocardial hypertrophy and may, therefore, provide a new treatment option to prevent sudden cardiac death in patients with hypertrophic cardiomyopathy.
Martin Penicka; Pavel Gregor; Roman Kerekes; Dan Marek; Karol Curila; Jiri Krupicka;
Related Documents :
8333984 - A reversible form of apical left ventricular hypertrophy associated with pheochromocytoma.
144034 - Cardiac size and function in acromegaly.
11113004 - Metabolic adaptation of the hypertrophied heart: role of the malate/aspartate and alpha...
17324134 - Differences between pathological and physiological cardiac hypertrophy: novel therapeut...
8005134 - Double ventricular responses during extrastimulation of atrioventricular nodal reentran...
1999634 - Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery di...
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't     Date:  2008-12-12
Journal Detail:
Title:  The Journal of molecular diagnostics : JMD     Volume:  11     ISSN:  1525-1578     ISO Abbreviation:  J Mol Diagn     Publication Date:  2009 Jan 
Date Detail:
Created Date:  2008-12-30     Completed Date:  2009-05-05     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100893612     Medline TA:  J Mol Diagn     Country:  United States    
Other Details:
Languages:  eng     Pagination:  35-41     Citation Subset:  IM    
Cardiocenter, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Data Bank Information
Bank Name/Acc. No.:
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / administration & dosage*
Benzimidazoles / administration & dosage*
Blood Pressure / drug effects
Cardiac Myosins / genetics
Cardiomyopathy, Hypertrophic / complications*,  drug therapy,  genetics,  physiopathology
Carrier Proteins / genetics
Double-Blind Method
Hypertrophy, Left Ventricular / drug therapy*,  genetics,  physiopathology
Middle Aged
Myosin Heavy Chains / genetics
Pilot Projects
Tetrazoles / administration & dosage*
Time Factors
Treatment Outcome
Ventricular Function, Left / drug effects*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Benzimidazoles; 0/Carrier Proteins; 0/Myosin Heavy Chains; 0/Tetrazoles; 0/myosin-binding protein C; EC 3.6.1.-/Cardiac Myosins; S8Q36MD2XX/candesartan
Comment In:
J Mol Diagn. 2009 Jan;11(1):12-6   [PMID:  19056845 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Detection of cytomegalovirus in whole blood using three different real-time PCR chemistries.
Next Document:  Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.